You are here

Histogenics

Battered and out of options, Histogenics turns to eye drug developer Ocugen for reverse merger

Endpoints

Mon, 04/8/19 - 12:01 pm

Histogenics to lay off 65% of workforce, including CMO & CBO, in restructuring

Mass Device

Thu, 01/24/19 - 11:30 pm

Histogenics appoints a new CEO | Personnel Moves

Mass Device

Tue, 06/11/13 - 10:43 pm

Histogenics drums up $49M for NeoCart trial

Tue, 07/24/12 - 08:48 pm

clinical trials

Histogenics CEO denies Israeli report of R&D layoffs | Personnel Moves

Fri, 06/3/11 - 01:13 pm